

1 **Innate lymphoid cell composition associates with COVID-** 2 **19 disease severity**

3
4 Marina García^{1†}, Efthymia Kokkinou^{1†*}, Anna Carrasco García¹, Tiphaine Parrot¹,
5 Laura M. Palma Medina¹, Kimia T. Maleki¹, Wanda Christ¹, Renata Varnaité¹, Iva
6 Filipovic¹, Hans-Gustaf Ljunggren¹, Niklas K. Björkström¹, Elin Folkesson^{2,3}, Olav
7 Rooyackers⁴, Lars I. Eriksson^{5,6}, Anders Sönnernborg^{2,7}, Soo Aleman^{2,7}, Kristoffer
8 Strålin^{2,7}, Sara Gredmark-Russ^{1,2}, Jonas Klingström^{1†}, Jenny Mjösberg^{1†} & the
9 Karolinska KI/K COVID-19 Study Group

10

11 ¹Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
12 Karolinska University Hospital, Stockholm, Sweden

13 ²Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

14 ³Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet,
15 Stockholm, Sweden.

16 ⁴Division of Anesthesiology and Intensive Care; Department of Clinical Science, Technology
17 and Intervention; Karolinska Institutet, Huddinge, Sweden

18 ⁵Department of Physiology and Pharmacology, Section for Anesthesiology and Intensive
19 Care, Karolinska Institutet, Stockholm, Sweden.

20 ⁶Function Perioperative Medicine and Intensive Care, Karolinska University Hospital,
21 Stockholm, Sweden.

22 ⁷Division of Infectious Diseases and Dermatology, Department of Medicine Huddinge,
23 Karolinska Institutet, Stockholm, Sweden.

24

25

26 † These authors contributed equally to this work

27 *Correspondence: efthymia.kokkinou@ki.se

28

29

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **ACKNOWLEDGEMENTS**

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

We express our sincere gratitude to all the patients and their families as well as the clinical personnel that helped to carry out the study as part of the Karolinska KI/K COVID-19 Immune Atlas.

64 **ABSTRACT**

65

66 **Objectives:** The role of innate lymphoid cells (ILCs) in coronavirus disease 2019
67 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-
68 CoV-2), is unknown. Understanding the immune response in COVID-19 could
69 contribute to unravel the pathogenesis and identification of treatment targets. To
70 describe the phenotypic landscape of circulating ILCs in COVID-19 patients and to
71 identify ILC phenotypes correlated to serum biomarkers, clinical markers, and
72 laboratory parameters relevant in COVID-19.

73

74 **Methods:** Blood samples collected from moderately (n=11) and severely ill (n=12)
75 COVID-19 patients as well as healthy control donors (n=16), were analyzed with 18-
76 parameter flow cytometry. Using supervised and unsupervised approaches, we
77 examined the ILC activation status and homing profile. Clinical and laboratory
78 parameters were obtained from all COVID-19 patients and serum biomarkers were
79 analyzed with multiplex immunoassays.

80

81 **Results:** ILCs were largely depleted from the circulation of COVID-19 patients
82 compared with healthy controls. Remaining circulating ILCs from patients revealed
83 increased frequencies of ILC2 in moderate COVID-19, with a concomitant decrease
84 of ILC precursors (ILCp), as compared with controls. ILC2 and ILCp showed an
85 activated phenotype with increased CD69 expression, whereas expression levels of
86 the chemokine receptors CXCR3 and CCR4 were significantly altered in ILC2 and
87 ILCp, and ILC1, respectively. The activated ILC profile of COVID-19 patients was
88 associated with soluble inflammatory markers, while frequencies of ILC subsets were
89 correlated with laboratory parameters that reflect the disease severity.

90

91 **Conclusion:** This study provides insights into the potential role of ILCs in immune
92 responses against SARS-CoV-2, particularly linked to the severity of COVID-19.

93

94 **Keywords:** Innate lymphoid cells, coronavirus, COVID-19, SARS-CoV-2, immune
95 response, respiratory viral infection.

96

97 INTRODUCTION

98 Coronavirus disease 2019 (COVID-19), caused by the novel severe acute
99 respiratory syndrome coronavirus 2 (SARS-CoV-2), is of global concern and major
100 efforts to identify effective treatments and vaccines are currently underway¹⁻⁴. SARS-
101 CoV-2 affects mainly the respiratory tract and infected individuals often present with
102 flu-like symptoms. While some patients recover within weeks, others progress to a
103 severe stage of disease, typically including severe respiratory distress and hypoxia
104 with later multi-organ failure, occasionally leading to death^{5,6}. Notably, a gradual
105 progression to more severe disease stages coincides with the development of a
106 hyperactivated immune response, triggering a systemic cytokine storm circulatory
107 impairment, sometimes leading to circulatory shock⁷⁻⁹. Thus, there are reasons to
108 believe that immunopathology involving the innate immune system plays a potent role
109 behind severe morbidity and mortality in the critically ill COVID-19 patients. Currently,
110 little information is available on the role of innate immune cells in COVID-19.
111 Therefore, here we studied the role of innate lymphoid cell (ILC) in hospitalized
112 COVID-19 patients.

113 ILCs are innate lymphocytes which, unlike T- and B-cells, lack rearranged
114 antigen specific receptors and cell surface markers associated with other lymphoid
115 and myeloid lineages¹⁰. ILCs are categorized into five major groups: natural killer (NK)
116 cells, ILC1, ILC2, ILC3 and Lymphoid Tissue Inducer (LTi) cells¹⁰. Based on their
117 transcription factor dependence and functional characteristics, ILC1^{11,12}, ILC2¹³⁻¹⁵ and
118 ILC3¹⁶ are considered the innate counterparts of the specialized subsets of CD4⁺ T
119 cells, i.e. Th1, Th2 and Th17 cells, respectively, while NK cells mirror the cytotoxic
120 functions of CD8⁺ T cells¹⁰. Although ILCs exert their function primarily in tissues,
121 distinct subsets of ILCs are found circulating in blood^{17,18}. The major blood ILC
122 population is the precursor ILC (ILCp), with the capacity to home to peripheral tissues
123 and differentiate to mature ILC subsets¹⁸. However, human blood also harbors the
124 committed ILC lineages ILC1 and ILC2. ILC2 in blood express CRTH2 and CD161
125 and are dependent on the GATA binding protein-3 (GATA-3) transcription factor¹⁹.
126 IFN- γ -producing ILCs, reminiscent of ILC1, have been identified in peripheral blood²⁰.
127 While their characterization has been challenging due to the lack of unique surface
128 markers²¹, studies have shown that blood ILC1 that produce IFN- γ express the

129 chemokine receptor CXCR3²⁰. Hence, CXCR3 serves as a marker to define the ILC1
130 subset in peripheral blood.

131 While little is known regarding ILCs in the context of human respiratory viral
132 infections, studies performed in mice highlight their contribution during acute viral
133 infection. More specifically, ILC2 have been suggested to accumulate in the lung of
134 influenza virus-infected mice and promote lung homeostasis and tissue repair²². In
135 contrast, ILC2 in concordance with T cells, were reported to contribute to allergic
136 airway inflammation induced by influenza virus in mice²³. In humans, ILCs have been
137 investigated in acutely HIV-1-infected individuals where they were found to be
138 depleted from the circulation²⁴. To the best of our knowledge, ILCs have not yet been
139 investigated in a human respiratory viral disease.

140 Understanding the immunopathogenesis of COVID-19 is urgently needed in
141 order to help tackle the current pandemic. In the present study, we report a profound
142 reduction in number of ILCs within the systemic circulation of COVID-19 patients. The
143 remaining ILCs show dysregulated expression of markers associated with activation
144 and migration. Furthermore, ILC frequencies are correlated to clinical parameters
145 related to COVID-19 disease severity.

146

147 **MATERIAL AND METHODS**

148

149 **Study participants and sampling**

150 As a part of the Karolinska KI/K COVID-19 Immune Atlas, 23 COVID-19
151 patients (6 females and 17 males; median age 57 years; age range 18 - 74 years)
152 positive for SARS-CoV-2 RNA by diagnostic RT-qPCR and hospitalized at the
153 Karolinska University Hospital (Stockholm, Sweden) were included in the present
154 study. Patients were classified as COVID-19 moderate (n=11) and severe (n=12),
155 based on the peak supplementary oxygen received during hospitalization until the time
156 of inclusion in the study. The moderate group required low or no supplementary
157 oxygen (low oxygen flow, $\leq 15\text{L}/\text{min}$), out of whom 8 were hospitalized in the regular
158 ward and 3 in the intensive care unit (ICU). These patients had median ordinal scale
159 of 5 (IQR 4-5) at sampling. The severe group consisted of patients that were
160 hospitalized in the ICU and required mechanical ventilation or extracorporeal
161 membrane oxygenation (ECMO; one patient) provided within an intensive care setting.
162 These patients had a median ordinal scale score of 7 (IQR 7-7) at sampling. This

163 classification was in line with the 8-category ordinal scale described by Beigel *et al* as
164 well as in the WHO guidelines^{25,26}.

165 Peripheral blood sample from all COVID-19 patients was collected 5 to 24 days
166 (median 14 days; IQR 5-24 days) after symptom debut and 0 to 8 days after
167 hospitalization.

168 Sixteen donors (6 females and 10 males; median age 54 years; age range
169 between 34 - 69 years), all SARS-CoV-2 IgG seronegative and symptom-free at the
170 day of sampling, were included as a control group for this study. Detailed donor
171 characteristics are summarized in Tables 1-2.

172 This study was approved by the Swedish Ethical Review Authority and
173 conducted according to the Declaration of Helsinki. All patients or next of kin and
174 control donors provided oral and/or written informed consent in line with the ethical
175 approval.

176

177 **Serum collection and cell isolation from whole blood**

178 Peripheral blood mononuclear cells (PBMCs) from control donors and COVID-
179 19 patients were isolated from heparinized anti-coagulated blood in SepMate tubes
180 (Stemcell Technologies) using gradient density centrifugation, according to
181 manufacturer's instructions. Briefly, 15ml of LymphoprepTM (Stemcell Technologies)
182 was pipetted below the SepMate insert and 20ml of diluted whole blood was dispensed
183 on top. Tubes were centrifuged at 1200 *g* for 10 min. The supernatant including
184 PBMCs was carefully decanted into a new tube, followed by two washes with PBS
185 containing 10% FCS. Platelets were removed by centrifuging the samples at 400 *g*
186 for 10 min. Pellets were resuspended, cells counted and subsequently stained for flow
187 cytometry.

188 Serum was collected from COVID-19 patients and control donors in BD
189 Vacutainer serum tubes with spray-coated silica (BD Biosciences). After coagulation
190 for up to 2 hours at room temperature (RT), serum was isolated by centrifugation at
191 2000 *g* for 10 min and immediately stored at -80 °C for later analysis.

192

193 **Cell staining and flow cytometry analysis**

194 Freshly isolated PBMCs were stained with dead cell marker (Invitrogen) and
195 fluorochrome-conjugated antibodies directed against intracellular and surface markers
196 (See Table S1 in the Online Repository) for 20 min at RT in the dark. Cells were

197 washed two times with 150 ul of PBS with 10% FCS. Next, pellets were resuspended
198 in 100 ul of BD FACS Lysing Solution (BD Biosciences) and incubated for 10 min at
199 RT, for cell fixation. After washing with PBS with 10% FCS, cells were permeabilized
200 using 100 ul of BD Perm2 Permeabilizing Solution (BD Biosciences) for 10 min at RT.
201 Subsequently, antibodies were added for intracellular staining and incubated for 30
202 min at RT in the dark. Cells were then washed with 150 ul of PBS with 10% FCS and
203 incubated in a 1% formaldehyde solution for 2h, washed and resuspended in PBS
204 containing 10% FCS.

205 The antibodies and dead cell marker used for flow cytometry staining are listed
206 in Supplementary Table III. Samples were acquired on a BD LSR Fortessa™. Flow
207 cytometric analysis was performed using FlowJo version 10.6.2 (TreeStar).

208

209 **UMAP analysis**

210 To ensure unbiased manual gating, a blinded analysis was implemented,
211 whereby all FCS3.0 files were renamed and coded by one person and blindly analyzed
212 by another person. All samples were compensated electronically and gatings were
213 based on fluorescent-minus-one (FMO) or negative controls. After all gatings were
214 performed, samples were decoded and statistical analysis between groups and
215 unsupervised analysis was performed. For unsupervised analysis, the following
216 FlowJo plugins were used: DownSample (v.1.1), UMAP (v.2.2), Phenograph (v.2.4)
217 and ClusterExplorer (v.1.2.2) (all FlowJo LLC). First, 133 events per patients were
218 downsampled from the total ILC gate (Fig. 2SB). The new generated FCS files were
219 labelled according to control or patient group (moderate or severe COVID-19) and
220 concatenated per group. Subsequently, all groups were taken to the same number of
221 events, by downsampling to the number of events present in the group with the least
222 number of events. The three new FCS files corresponding to control, moderate and
223 severe COVID-19 patients were then concatenated for dimensionality reduction
224 analysis using UMAP. UMAP was run including the markers CRTH2, CD161, CD117,
225 CD69, HLA-DR, Ki-67, CD45RA, CD62L, CCR4, CCR6, CXCR3, CD56, NKp44 and
226 using the following parameters: metric = euclidean, nearest neighbors = 15, and
227 minimum distance = 0.5. Clusters of phenotypically related cells were identified using
228 Phenograph plugin and including the same markers as for UMAP and parameters k =
229 30 and Run ID = auto. Finally, ClusterExplorer plugin was used to study the phenotype

230 of the different clusters and to generate heatmaps of marker expression from those
231 clusters.

232

233 **Absolute cell counts**

234 Absolute numbers of ILCs in peripheral blood were obtained using BD
235 Multitest™ 6-color TBNK reagents with bead-containing BD Trucount™ tubes (BD
236 Biosciences), according to manufacturer's instructions. Briefly, 50 µL of anti-
237 coagulated whole blood were added into Trucount tubes within 3h after blood
238 extraction. Then, an antibody mix was added for staining. After 15 minutes of
239 incubation at RT in the dark, stained whole blood was fixed and red blood cells lysed
240 with 1X BD FACS Lysing Solution (BD Biosciences) for 2h at RT. Samples were then
241 fixed with 1% PFA for 2h prior to acquisition in a FACSymphony A5 (BD Biosciences)
242 flow cytometer. Absolute ILC cell counts were calculated using the formula:

243
$$\text{ILC (\#/mL)} = [(\# \text{ lymphocytes events acquired} * \text{ total \#beads in tube} * 1000) /$$

244
$$(\# \text{beads acquired} * \text{ volume of whole blood stained (\mu L)})] * \% \text{ ILC out of lymphocytes.}$$

245 ILC1, ILC2 and ILCp absolute counts were calculated using their frequencies relative
246 to total ILCs.

247

248 **Analysis of serum biomarkers**

249 Heat-inactivated (56°C for 30 min) serum from all patients and controls were
250 analyzed for soluble protein biomarkers using proximity extension assay (PEA)
251 technology (Olink AB, Uppsala, Sweden). The samples were analyzed using the
252 inflammation (v.3022) panel, including a total of 92 analytes. Data are expressed as
253 normalized protein expression (NPX) values. NPX is an arbitrary unit on a Log2 scale
254 to normalize data to minimize both intra-assay and inter-assay variation.

255 Additionally, several soluble analytes were also measured in serum or plasma
256 by use of custom made multiplex Magnetic Luminex Screening assays (R&D
257 Systems), according to the manufacturer's instructions. Serum and plasma were
258 diluted 1:2 prior to analysis in multiplex.

259 Analytes from Olink data and Magnetic Luminex Screening assays that had
260 more than 33% and 25% of missing values, respectively, were excluded from analysis.
261 Left-censored data from the multiplex analysis were imputed using *GSimp* package²⁷
262 in R (v. 3.6.0)²⁸.

263

264 **Clinical parameters and serology**

265 Serum samples from all patients and controls were analyzed for presence of
266 SARS-CoV- 2 antibodies, as recently described²⁹.

267 Micro-neutralization assay for measurement of neutralizing antibody titers was
268 performed as previously described³⁰. Briefly, heat inactivated serum (56°C for 30
269 minutes) was diluted two-fold starting at 1:10, mixed with an equal volume of 200
270 TCID50 SARS-CoV-2 (50 µl diluted serum plus 50 µl virus) and incubated for 1 hour
271 at 37 °C and 5% CO₂. Mixtures were then added to Vero E6 cells and incubated at
272 37 °C 5% CO₂ for four days. Cells were inspected for signs of cytopathic effect (CPE)
273 by optical microscopy. Results were expressed as the arithmetic mean of the
274 reciprocals of the highest neutralizing dilutions from the two duplicates for each
275 sample.

276

277 **Statistical analysis**

278 Statistical analyses were performed using Prism version 8.4.3 (GraphPad
279 Software Inc.). For comparisons between three unpaired groups, Kruskal-Wallis test
280 followed by Dunn's multiple comparisons test was used. Correlation analyses were
281 performed using Spearman's rank correlation. Spearman's correlation matrix was
282 generated with R (v.4.0.2) using package corrplot (v.0.84). Statistical significance for
283 differences between COVID-19 patients and healthy controls was determined by two-
284 sided Mann-Whitney *U* test. *p*-values < 0.05 were considered statistically significant.

285 Principal component analysis (PCA) was performed in R (v.4.0.2; R Core Team,
286 2020) using packages Factoextra (v.1.0.7)³¹, FactoMineR (v.2.3)³², RColorBrewer
287 (v.1.1-2)³³, and ggplot2 (v.3.3.2)³⁴. Data was normalized in R using the *scale* argument
288 within the PCA function. Where data was missing, the values were imputed using
289 package WaverR (v1.0)³⁵ using 1000 repetitions.

290

291 **RESULTS**

292 A total of twenty-three patients with either moderate (n=11) or severe (n=12)
293 COVID-19 and sixteen control donors were included in the study (Fig. 1A). The
294 COVID-19 patients showed profound perturbations in inflammatory markers,
295 coagulation factors, organ/muscle damage markers as well as biochemical and
296 hematological parameters (Fig. S1). A detailed summary of the patients' clinical and

297 laboratory parameters is presented in Tables 1-2. A timeline summarizing the major
298 clinical events of the patients is shown in Fig. 1B.

299 For the identification and analysis of peripheral blood ILCs we used 18-
300 parameter flow cytometry and a modification of a well-established gating strategy³⁶
301 (Fig. S2A). We found that the relative frequencies and absolute counts of total CD127⁺
302 ILCs (hereafter referred to as total ILCs), as well as the absolute counts of the specific
303 subsets ILC1, ILC2 and ILCp, were decreased in peripheral blood of COVID-19
304 patients as compared with controls (Fig. 2A-D). Further characterization of the
305 remaining circulating ILC compartment showed reduced ILCp frequencies in COVID-
306 19 patients, while the frequencies of ILC1 remained unchanged (Fig. 2C and E). Of
307 note, the moderately ill group showed elevated frequencies of both total ILC2 (Fig. 2E)
308 and CD117⁺ ILC2, as compared with the control group (Fig. 2F).

309 Taken together, we observed a general ILC depletion as well as compositional
310 changes in the circulating ILC compartment of COVID-19 patients. Interestingly,
311 changes in the relative frequency of ILCs differed between the moderate and severe
312 group, prompting a more detailed phenotypical study of the ILCs.

313 To deepen our understanding of the differentiation, activation, and migration of
314 ILCs during COVID-19, we assessed differentiation (CD56 and NKp44) (Fig. S3A and
315 B) and activation (CD69, HLA-DR and Ki-67) markers as well as chemokine receptors
316 (CCR4, CCR6 and CXCR3) and molecules associated with naivety and homing to
317 lymphoid tissues (CD45RA and CD62L) on ILCs (Fig. 3A-H). Manual gating and
318 unbiased principal component analysis (PCA) were used to simultaneously take into
319 account the relative frequency of all the markers measured on ILCs.

320 This approach revealed a higher relative frequency of CD69-expressing total
321 ILCs in patients as compared with controls (Fig. 3A). Additionally, Ki-67, a marker of
322 cell proliferation, was increased in severe compared with moderate COVID-19 but
323 decreased in moderate COVID-19 compared with controls (Fig. 3A). However, the
324 overall Ki-67 expression level was low in all ILCs regardless of the study group,
325 suggesting either a low proliferating capacity of ILCs in peripheral blood or migration
326 of proliferative ILCs to tissues at an earlier stage. In line with an increase in CD69 in
327 COVID-19 patients, we detected reduced frequencies of total ILCs expressing
328 CD45RA and CD62L, two markers associated with ILC naivety¹⁸, in severe COVID-19
329 patients (Fig. 3A). Additionally, we observed alterations in chemokine receptor
330 expression between controls and moderate COVID-19 patients, revealing a reduction

331 in the percentage of CXCR3⁺ and an increase in CCR4⁺ ILCs. The latter likely reflects
332 the increase in ILC2 frequencies in these patients (Fig. 2E), as CCR4 is particularly
333 highly expressed on ILC2 (Fig. 3E). Despite these changes in ILC phenotypes, the
334 PCA analysis could not discriminate between COVID-19 patients and controls on the
335 basis of the total ILC data (Fig. 3B), suggesting that the COVID-19 related changes in
336 total ILCs are ILC subset specific.

337 Indeed, we observed no changes in expression of markers associated with
338 differentiation and activation in ILC1. There was, however, a slightly increased
339 percentage of CCR4⁺ ILC1 cells in COVID-19 patients compared to controls (Fig. 3C).
340 We also detected a reduction of CD56⁺ ILC1 in COVID-19 patients (Fig. S3A). PCA
341 analysis illustrated these differences well, showing segregation of the ILC1 data on
342 the basis of CCR4 for COVID-19 patients and CD56 for controls (Fig. 3D).

343 In contrast, ILC2 displayed an activated phenotype in COVID-19 patients,
344 showing higher frequencies of CD69⁺ and a tendency towards reduced frequencies of
345 CD62L⁺ cells, as compared with controls (Fig. 3E). Interestingly, Ki-67, generally
346 expressed at very low levels, was decreased in relative frequency in ILC2 from severe
347 COVID-19 patients compared to the control group, possibly reflecting tissue
348 recruitment of such cells in severe COVID-19. Indeed, we identified dysregulated
349 chemokine receptor expression on ILC2 in COVID-19 patients, specifically CXCR3
350 which was reduced in the patients as compared with controls (Fig. 3E). PCA analysis
351 provided an illustration of these findings by segregating the ILC2 data from patients
352 and controls based on CD69 expression for patients and chemokine receptors as well
353 as CD62L and CD45RA for the controls (Fig. 3F). The latter two were, however, not
354 statistically different between the groups (Fig. 3E).

355 ILCp showed an activated profile in COVID-19 patients, with increased CD69
356 and HLA-DR expression as compared with controls. Additionally, CXCR3 was
357 decreased on ILCp in COVID-19 patients as compared with controls (Fig. 3G).
358 Although PCA analysis did not separate the ILCp phenotype from patients and controls
359 clearly, there was a tendency towards separation of ILCp from controls on the basis
360 of CD62L and CD45RA (Fig. 3H). These two markers showed reduced tendency but
361 were not statistically significant in the manual gating (Fig. 3G).

362 Overall, these findings suggest that the ILCs remaining in the circulation of
363 COVID-19 patients are activated and show an altered expression of chemokine

364 receptors, particularly a decrease in CXCR3, possibly reflecting alterations in CXCR3-
365 ligand dependent ILC recruitment to tissues.

366 Uniform Manifold Approximation and Projection (UMAP) analysis confirmed
367 and extended the findings obtained by manual gating in an unsupervised manner. As
368 expected from manual gating, clear differences in ILC composition between controls
369 and COVID-19 patients were observed when overlaying each group to the UMAP
370 containing all concatenated ILC events (Fig. 4A, S2B). Phenograph clustering yielded
371 a total of 14 distinct clusters across patients and controls (Fig. 4B). Based on the
372 relative expression of CRTH2, CD117 and CXCR3, clusters were identified as ILC1,
373 ILC2 or ILCp (Fig. 4C-D). Thereafter, manually defined ILC subset gates that were
374 overlaid into the UMAP (Fig. 4E) showed a similar spatial distribution as the
375 Phenograph-defined clusters belonging to each ILC subset, confirming the precision
376 of the manual gating relative to the unsupervised analysis (Fig. 4B).

377 Next, we assessed each Phenograph-defined cluster. Validating the manual
378 gating, CCR4⁺ ILC1 (cluster 14) was uniquely present in COVID-19 patients, while two
379 additional CCR4^{-/lo} ILC1 clusters (2 and 6) were overrepresented in severe COVID-19
380 patients (Fig. 4F, G). For ILC2, cluster 8, containing CCR4^{hi} ILC2, was only present in
381 COVID-19 patients and other two CCR6⁺ ILC2 clusters (10, 12) were accumulated in
382 moderate patients (Fig. 4F, H). Corroborating again the findings from manual gating
383 (Fig. 3), cluster 3, uniquely present in COVID-19 patients, corresponded to activated
384 (CD69⁺) ILCp lacking CXCR3 (Fig. 4F, I). Furthermore, three ILCp clusters (1, 5, and
385 7) with an immature phenotype (CD45RA^{+/hi}/CD62L^{+/hi}) were reduced in COVID-19
386 patients as compared with controls (Fig. 4F, I), in support of the data obtained by
387 manual gating (Fig. 3).

388 Altogether, the unsupervised analysis revealed clusters specifically
389 accumulated in COVID-19 patients compared to controls and the presence of specific
390 ILC phenotypes that associated to the disease severity. Importantly, several of the
391 findings agreed with those obtained by manual gating. Specifically, we confirmed an
392 increase in the relative frequency of CD69⁺ ILCp and a decrease in CXCR3⁺ ILCp in
393 both moderate and severe COVID-19, an increase in ILC2 percentage specifically in
394 moderate COVID-19 and an increased CCR4 expression among ILC1 in the patients.

395 To analyze for potential factors involved in the activation and potential
396 recruitment of ILCs to tissues in the COVID-19 patients, we examined correlations
397 between ILCs and a wide array of soluble serum factors (Fig. S5A-B). Based on our

398 findings on altered frequencies of CXCR3⁺ and CD69⁺ ILCs in COVID-19 (Fig. 3A),
399 we focused on selected chemokines (CCL20, CXCL10 and CXCL11) and factors
400 previously reported to be increased in COVID-19 or other viral respiratory disease: IL-
401 6, IL-10, IL18R1 and PD-L1^{7-9,37-42}. Interestingly, we found that the percentage of
402 activated (CD69⁺) total ILCs and activated ILCp positively correlated with serum IL-6
403 levels in the COVID-19 patients (Fig. 5A). Additionally, the relative levels of the
404 cytokine IL-10 also positively correlated with the levels of CD69⁺ ILCs in the COVID-
405 19 patients (Fig. 5B). Moreover, the percentage of CD69⁺ total ILCs and ILCp
406 positively correlated with CXCL10 levels in the COVID-19 patients (Fig. 5C),
407 suggesting that this chemokine is related to the increase in the percentage of activated
408 ILCs that remain in the circulation of COVID-19 patients.

409 Furthermore, indicative of dysregulated ILC tissue migration in COVID-19, we
410 observed a negative correlation of CXCL10 and CXCL11 levels (CXCR3 ligands), with
411 the percentage of CXCR3⁺ ILCs in COVID-19 patients (Fig. 5D). Additionally, the
412 percentage of CCR4⁺ total ILCs and ILC2 negatively correlated with CCL20 (ligand for
413 CCR6) levels. The latter correlation is in line with the high expression of CCR6 on
414 circulating ILC2 (ref. 17) (Fig. 5E).

415 Of further interest, IL18R1 and PD-L1, involved in type 1-inflammation^{40,43}
416 negatively correlated with the level of CD45RA⁺ ILCp, suggesting that the
417 inflammatory status of COVID-19 patients may promote maturation, depletion and/or
418 tissue migration of ILCp in the systemic circulation (Fig. S5C).

419 We next sought to integrate our flow cytometric data with the clinical and
420 laboratory findings from the same patients. Clinical information and laboratory
421 measurements (summarized in Tables 1-2) integrated in a PCA analysis clustered the
422 patients on the basis of disease severity (Fig. 6A) with several hematological and
423 biochemical factors particularly driving this separation (Fig. 6B).

424 We searched for potentially relevant correlations between ILCs and the clinical
425 and laboratory parameters. The frequencies of ILC1 and ILC2 correlated with several
426 of the measured parameters, whereas no correlations were found for ILCp frequencies
427 (Fig. S3B). The percentage of ILC1 positively correlated with LDH levels, which was
428 significantly increased in severe COVID-19 patients (Fig. 6C, Fig. S1). ILC1
429 frequencies also positively correlated with parameters that did not differ between the
430 two COVID-19 patient groups, i.e. platelet counts, serum SARS-CoV-2 IgG levels and
431 days post symptom debut (Fig. 6C). The percentage of ILC2, on the other hand,

432 negatively correlated with the leukocyte, neutrophil and platelet count (Fig. 6D).
433 Interestingly, high neutrophil levels, which have been described as partial predictors
434 of disease severity⁴⁴, also contributed heavily to the separation between patient
435 groups in the current study (Fig. 6A-B). Of note, neutrophils have been found to inhibit
436 ILC2 function, thus preventing allergic airway inflammation⁴⁵. Additionally, the relative
437 frequency of ILC2 correlated negatively with levels of D-dimer, a coagulation factor
438 that has been suggested as a systemic biomarker of disease severity in COVID-19
439 (Fig. 6D)^{44,46}. Finally, we observed a negative correlation between ILC2 frequencies
440 and organ/muscle damage markers (myoglobin, troponin T, LDH) and the number of
441 days since symptom debut (Fig. 6D). These findings suggest that among COVID-19
442 patients, elevated frequencies of ILC1 and decreased frequencies of ILC2 are
443 hallmarks of COVID-19 patients with a clinical profile associated with severe disease.

444

445 **DISCUSSION**

446 We report unphysiologically-reduced levels of ILCs in the circulation of COVID-
447 19 patients, both in percentage and absolute counts, in line with a recent report⁴⁷, and
448 the overall reduction of peripheral blood lymphocytes described in COVID-19^{6,38,48,49}.
449 In addition to the overall ILC depletion, we found major changes in the residual
450 circulating ILC compartment in COVID-19 patients, including altered frequencies of
451 ILC subsets, increased activation and dysregulated migration receptor expression.
452 Our data imply that the circulating ILCs are activated and have differentiated and/or
453 are differentially recruited to tissues where they may contribute to the anti-viral
454 defense.

455 Noteworthy, we found increased circulating ILC2 frequencies in moderate but
456 not severe COVID-19 patients, suggesting that ILC2 may be differentially regulated
457 dependent on severity of disease. Supporting this, the relative frequency of ILC2 in
458 COVID-19 patients correlated negatively with the coagulation factor D-dimer,
459 previously shown to be associated with the development of severe disease^{44,46} as well
460 as organ/muscle damage markers, suggesting that low ILC2 levels in COVID-19
461 patients could be indicative of a more severe disease outcome. Indeed, ILC2 have
462 been shown to have a prominent role in lung tissue repair during influenza A infection
463 in mice²². This was achieved through production of the epidermal growth factor related
464 protein amphiregulin, also shown to be involved in promotion of regulatory T cells and
465 cell survival in hepatitis C virus infection^{50,51}. The role for ILC2-derived amphiregulin

466 in lung tissue repair in humans is unknown and deserves further exploration in COVID-
467 19.

468 In contrast to ILC2, ILCp frequencies were diminished in COVID-19 patients as
469 compared with controls, suggesting their migration to the site of infection or
470 differentiation into mature ILC subsets in the circulation. This has previously been
471 described in an adoptive transfer mouse model¹⁸. In support of this hypothesis, both
472 ILC2 and ILCp showed an activated phenotype, based on increased frequencies of
473 CD69⁺ and/or HLA-DR⁺ cells. This is in line with the recent discovery of increased
474 frequencies of CD69⁺ NK cells in COVID-19⁵². Interestingly, in addition to its known
475 role as an early activation marker, CD69 is also a marker of tissue residency⁵³. Thus,
476 the presence of the CD69-expressing ILCs in circulation could also indicate retrograde
477 migration from tissue to circulation after local tissue activation, as recently shown for
478 resident memory T cells⁵⁴. Furthermore, we observed that the CD69-expressing cells
479 in the circulation of COVID-19 patients positively correlated with the levels of IL-6 and
480 IL-10, suggesting that the inflammatory status in these patients could be the driver of
481 ILC activation and/or recirculation. Additionally, these CD69-expressing cells
482 positively correlated with the chemokine CXCL10 in patients. In contrast, CXCR3⁺
483 ILCs negatively correlated with CXCR3 ligands CXCL10 and CXCL11, potentially
484 indicating a CXCR3-dependent tissue migration of ILCs in COVID-19. CXCR3⁺ ILCs
485 includes IFN- γ producing ILC1 (ref. 11,20), which are accumulated in acute and
486 chronic intestinal inflammation in humans¹¹. While ILC1 are essential for clearance of
487 cytomegalovirus in mice⁵⁵, the role for ILC1 in human anti-viral immunity, including
488 COVID-19, remains obscure and requires further exploration.

489 Lastly, the phenotypic characterization of circulating ILCs performed in this
490 study would benefit from additional analyses delineating the functionality of ILCs as
491 well as the impact of the tissue microenvironment to their phenotype and function. Of
492 special interest would be the study of ILCs from tissue resident sites, such as lung and
493 intestine, which have been described as main sites of SARS-CoV-2 infection and
494 shedding⁵⁶⁻⁵⁹. We have previously reported increased ILC2 frequencies in the
495 intestine of patients with inflammatory bowel disease¹⁷ and in the lungs of patients with
496 asthma⁶⁰, likely due to their influx from the circulation. In line with this, it is possible
497 that the lower ILC frequencies observed in severe as compared with moderate COVID-
498 19 patients could indicate potential trafficking of ILC2 to inflamed infection sites. To

499 address whether elevated levels of circulating ILC2 constitute a correlate of protection
500 in COVID-19 patients, further studies at the tissue level are required.

501 In summary, this study provides a phenotypic characterization of circulating
502 ILCs of COVID-19 patients. We identified that altered frequencies of ILCs correlate
503 with clinical and laboratory parameters linked to COVID-19 disease severity. Lastly, to
504 the best of our knowledge, this is the first comprehensive study of ILCs in the context
505 of a human respiratory viral infection. Thus, these data pave the way for a better
506 understanding of the role of this innate immune cell compartment in other viral
507 infectious diseases.

508

509

510 **AUTHOR CONTRIBUTION**

511 M.G.: conceptualization, data curation, formal analysis, investigation, methodology,
512 and writing-original draft; E.K.: conceptualization, data curation, formal analysis,
513 investigation, methodology, and writing-original draft; A.C.G.: conceptualization,
514 investigation, methodology, and writing-review and editing; T.P.: conceptualization,
515 methodology, and writing-review and editing; L.M.P.M.: Conceptualization, data
516 curation, formal analysis, and writing-review and editing; K.T.M.: conceptualization,
517 methodology, and writing-review and editing; W.C.: conceptualization, methodology,
518 and writing-review and editing; R.V.: conceptualization, resources, and writing-review
519 and editing; I.F.: conceptualization, resources, and writing-review and editing; H.G.L.:
520 conceptualization, funding acquisition, and writing-review and editing; N.K.B:
521 conceptualization and writing-review and editing; E.F.: methodology and writing-
522 review and editing; O.R.: conceptualization, methodology, and writing-review and
523 editing; L.I.E.: conceptualization and writing-review and editing; A.S.:
524 conceptualization and writing-review and editing; S.A.: conceptualization,
525 methodology, and writing-review and editing; K.S.: conceptualization, methodology,
526 investigation, and writing-review and editing; S.G.R.: conceptualization, investigation,
527 and writing-review and editing; J.K.: conceptualization, investigation, supervision,
528 funding acquisition, and writing-original draft; J.M.: conceptualization, investigation,
529 supervision, funding acquisition, and writing-original draft; Karolinska KI/K COVID-19
530 Study Group: conceptualization, methodology, and writing-review and editing.

531

532

533 **FUNDING SOURCES**

534 This study was supported by the Knut and Alice Wallenberg Foundation,
535 Nordstjernan AB, Swedish Research Council Vetenskapsrådet (VR), Karolinska
536 Institutet and the SciLifeLab COVID-19 National Program.

537

538 **CONFLICTS OF INTEREST**

539 The authors declare that the research was conducted in the absence of any
540 commercial or financial relationships that could be construed as a potential conflict of
541 interest. H.G.L. is a member of the board of XNK Therapeutics AB and Vycellix Inc.

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561 **REFERENCES**

562

563 1. Alijotas-Reig J, Esteve-Valverde E, Belizna C, et al. Immunomodulatory therapy
564 for the management of severe COVID-19. Beyond the anti-viral therapy: A
565 comprehensive review. *Autoimmun Rev* 2020; **19**(7).
566 doi:10.1016/j.autrev.2020.102569

567 2. Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through
568 large-scale compound repurposing. *Nature* 2020; **586**(7827): 113-119.
569 doi:10.1038/s41586-020-2577-1

570 3. Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine
571 development landscape. *Nat Rev Drug Discov* 2020; **19**(5): 305-306.
572 doi:10.1038/d41573-020-00073-5

573 4. Zhou P, Yang X Lou, Wang XG, et al. A pneumonia outbreak associated with a
574 new coronavirus of probable bat origin. *Nature* 2020; **579**(7798): 270-273.
575 doi:10.1038/s41586-020-2012-7

576 5. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and
577 moderate coronavirus disease 2019. *J Clin Invest* 2020; **130**(5): 2620-2629.
578 doi:10.1172/JCI137244

579 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
580 novel coronavirus in Wuhan , China. *Lancet* 2020; **395**(10223): 497-506.
581 doi:10.1016/S0140-6736(20)30183-5

582 7. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and
583 mechanisms of immunopathological changes in COVID-19. *Allergy Eur J Allergy*
584 *Clin Immunol* 2020; **75**(7): 1564-1581. doi:10.1111/all.14364

585 8. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19
586 cytokine storm: The anger of inflammation. *Cytokine* 2020; **133**: 155151.

- 587 doi:10.1016/j.cyto.2020.155151
- 588 9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-
589 19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020;
590 **395**(10229): 1033-1034. doi:10.1016/S0140-6736(20)30628-0
- 591 10. Vivier E, Artis D, Colonna M, et al. Innate Lymphoid Cells: 10 Years On. *Cell*.
592 2018; **174**(5): 1054-1066. doi:10.1016/j.cell.2018.07.017
- 593 11. Bernink JH, Peters CP, Munneke M, et al. Human type 1 innate lymphoid cells
594 accumulate in inflamed mucosal tissues. *Nat Immunol* 2013; **14**(3): 221-229.
595 doi:10.1038/ni.2534
- 596 12. Klose CSN, Kiss EA, Schwierzeck V, et al. A T-bet gradient controls the fate and
597 function of CCR6-ROR γ t + innate lymphoid cells. *Nature* 2013; **494**(7436): 261-
598 265. doi:10.1038/nature11813
- 599 13. Moro K, Yamada T, Tanabe M, et al. Innate production of TH 2 cytokines by
600 adipose tissue-associated c-Kit⁺ Sca-1⁺ lymphoid cells. *Nature* 2010;
601 **463**(7280): 540-544. doi:10.1038/nature08636
- 602 14. Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector
603 leukocyte that mediates type-2 immunity. *Nature* 2010; **464**(7293): 1367-1370.
604 doi:10.1038/nature08900
- 605 15. Price AE, Liang HE, Sullivan BM, et al. Systemically dispersed innate IL-13-
606 expressing cells in type 2 immunity. *Proc Natl Acad Sci U S A* 2010; **107**(25):
607 11489-11494. doi:10.1073/pnas.1003988107
- 608 16. Satoh-Takayama N, Vosshenrich CAJ, Lesjean-Pottier S, et al. Microbial Flora
609 Drives Interleukin 22 Production in Intestinal NKp46⁺ Cells that Provide Innate
610 Mucosal Immune Defense. *Immunity* 2008; **29**(6): 958-970.
611 doi:10.1016/j.immuni.2008.11.001

- 612 17. Forkel M, VanTol S, Höög C, Michaëlsson J, Almer S, Mjösberg J. Distinct
613 alterations in the composition of mucosal innate lymphoid cells in newly
614 diagnosed and established Crohn's disease and ulcerative colitis. *J Crohn's*
615 *Colitis* 2019; **13**(1): 67-78. doi:10.1093/ecco-jcc/jjy119
- 616 18. Lim AI, Li Y, Lopez-Lastra S, et al. Systemic Human ILC Precursors Provide a
617 Substrate for Tissue ILC Differentiation. *Cell* 2017; **168**(6): 1086-1100.e10.
618 doi:10.1016/j.cell.2017.02.021
- 619 19. Mjösberg J, Bernink J, Golebski K, et al. The Transcription Factor GATA3 Is
620 Essential for the Function of Human Type 2 Innate Lymphoid Cells. *Immunity*
621 2012; **37**(4): 649-659. doi:10.1016/j.immuni.2012.08.015
- 622 20. Roan F, Stoklasek TA, Whalen E, et al. CD4 + Group 1 Innate Lymphoid Cells
623 (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic
624 Sclerosis. *J Immunol* 2016; **196**(5): 2051-2062. doi:10.4049/jimmunol.1501491
- 625 21. Simoni Y, Fehlings M, Kløverpris HN, et al. Human Innate Lymphoid Cell
626 Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and
627 Frequency. *Immunity* 2017; **46**(1): 148-161. doi:10.1016/j.immuni.2016.11.005
- 628 22. Monticelli LA, Sonnenberg GF, Abt MC, et al. Innate lymphoid cells promote
629 lung-tissue homeostasis after infection with influenza virus. *Nat Immunol* 2011;
630 **12**(11): 1045-1054. doi:10.1038/ni.2131
- 631 23. Li BWS, de Bruijn MJW, Lukkes M, et al. T cells and ILC2s are major effector
632 cells in influenza-induced exacerbation of allergic airway inflammation in mice.
633 *Eur J Immunol* 2019; **49**(1): 144-156. doi:10.1002/eji.201747421
- 634 24. Kløverpris HN, Kazer SW, Mjösberg J, et al. Innate Lymphoid Cells Are Depleted
635 Irreversibly during Acute HIV-Infection in the Absence of Viral Suppression.
636 *Immunity* 2016; **44**(2): 391-405. doi:10.1016/j.immuni.2016.01.006

- 637 25. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of
638 Covid-19 — Preliminary Report. *N Engl J Med* 2020; **383**(10): 992-993.
639 doi:10.1056/nejmoa2007764
- 640 26. Coronavirus disease (COVID-19).
641 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
- 642 27. Wei R, Wang J, Jia E, Chen T, Ni Y, Jia W. GSimp: A Gibbs sampler based left-
643 censored missing value imputation approach for metabolomics studies. *PLoS*
644 *Comput Biol* 2018; **14**(1). doi:10.1371/journal.pcbi.1005973
- 645 28. R Core Team. R: A language and environment for statistical computing. R
646 Foundation for Statistical Computing, Vienna, Austria. [https://www.r-](https://www.r-project.org/)
647 [project.org/](https://www.r-project.org/).
- 648 29. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in
649 convalescent individuals with asymptomatic or mild COVID-19. *Cell* 2020;
650 **183**(1): 158-168.e14. doi:10.1101/2020.06.29.174888
- 651 30. Varnaité R, García M, Glans H, et al. Expansion of SARS-CoV-2- Specific
652 Antibody-Secreting Cells and Generation of Neutralizing Antibodies in
653 Hospitalized COVID-19 Patients. *J Immunol*. 2020. Epub ahead of print.
654 doi:10.4049/jimmunol.2000717
- 655 31. Kassambara, A. and Mundt F. factoextra: Extract and Visualize the Results of
656 Multivariate Data Analyses. R package version 1.0.7. [https://cran.r-](https://cran.r-project.org/web/packages/factoextra/index.html)
657 [project.org/web/packages/factoextra/index.html](https://cran.r-project.org/web/packages/factoextra/index.html).
- 658 32. Lê S, Josse J, Husson F. FactoMineR: An R package for multivariate analysis.
659 *J Stat Softw* 2008; **25**(1): 1-18. doi:10.18637/jss.v025.i01
- 660 33. Neuwirth E. RColorBrewer: ColorBrewer Palettes. R package version 1.1-2.
661 <https://cran.r-project.org/web/packages/RColorBrewer/index.html>.

- 662 34. Wickham H. ggplot2: Elegant Graphics for Data Analysis.
663 <https://ggplot2.tidyverse.org/>.
- 664 35. Cheronet, O., and Finarelli JA. WaverR: Data Estimation using Weighted
665 Averages of Multiple Regressions. [https://cran.r-](https://cran.r-project.org/web/packages/WaverR/index.html)
666 [project.org/web/packages/WaverR/index.html](https://cran.r-project.org/web/packages/WaverR/index.html).
- 667 36. Yudanin NA, Schmitz F, Flamar AL, et al. Spatial and Temporal Mapping of
668 Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity. *Immunity*
669 2019; **50**(2): 505-519.e4. doi:10.1016/j.immuni.2019.01.012
- 670 37. Liu F, Li L, Xu M Da, et al. Prognostic value of interleukin-6, C-reactive protein,
671 and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; **127**: 104370.
672 doi:10.1016/j.jcv.2020.104370
- 673 38. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinic outcome
674 of the SARS-CoV-2 infection. *Nature* 2020; **583**(7816): 437-440.
675 doi:10.1038/s41586-020-2355-0
- 676 39. Maleki KT, García M, Iglesias A, et al. Serum Markers Associated with Severity
677 and Outcome of Hantavirus Pulmonary Syndrome. *J Infect Dis* 2019; **219**(11):
678 1832-1840. doi:10.1093/infdis/jiz005
- 679 40. Schönrich G, Raftery MJ. The PD-1/PD-L1 axis and virus infections: A delicate
680 balance. *Front Cell Infect Microbiol* 2019; **9**: 207. doi:10.3389/fcimb.2019.00207
- 681 41. Zalinger ZB, Elliott R, Weiss SR. Role of the inflammasome-related cytokines Il-
682 1 and Il-18 during infection with murine coronavirus. *J Neurovirol* 2017; **23**(6):
683 845-854. doi:10.1007/s13365-017-0574-4
- 684 42. Harker JA, Godlee A, Wahlsten JL, et al. Interleukin 18 Coexpression during
685 Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by
686 Natural Killer Cells. *J Virol* 2010; **84**(8): 4073-4082. doi:10.1128/jvi.02014-09

- 687 43. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding
688 protein. *Front Immunol* 2013; **4**: 289. doi:10.3389/fimmu.2013.00289
- 689 44. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers.
690 *International Journal of Infectious Diseases* 2020; **95**: 304-307.
691 doi:10.1016/j.ijid.2020.04.061
- 692 45. Patel DF, Peiró T, Bruno N, et al. Neutrophils restrain allergic airway
693 inflammation by limiting ILC2 function and monocyte-dendritic cell antigen
694 presentation. *Sci Immunol* 2019;**4**(41): 7006. doi:10.1126/sciimmunol.aax7006
- 695 46. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
696 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*
697 2020; **395**(10229): 1054-1062. doi:10.1016/S0140-6736(20)30566-3
- 698 47. Kuri-Cervantes L, Pampena MB, Meng W, et al. Immunologic perturbations in
699 severe COVID-19/SARS-CoV-2 infection. *bioRxiv* [Preprint]. 2020;
700 doi:10.1101/2020.05.18.101717
- 701 48. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With
702 Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020; **71**(15):
703 762-768. doi:10.1093/cid/ciaa248
- 704 49. Wang F, Nie J, Wang H, et al. Characteristics of Peripheral Lymphocyte Subset
705 Alteration in COVID-19 Pneumonia. *J Infect Dis* 2020; **221**(11): 1762-1769.
706 doi:10.1093/infdis/jiaa150
- 707 50. Pei R, Chen H, Lu L, et al. Hepatitis C virus infection induces the expression of
708 amphiregulin, a factor related to the activation of cellular survival pathways and
709 required for efficient viral assembly. *J Gen Virol* 2011; **92**(10): 2237-2248.
710 doi:10.1099/vir.0.032581-0
- 711 51. Yuan CH, Sun XM, Zhu CL, et al. Amphiregulin activates regulatory T

- 712 lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in
713 hepatocellular carcinoma cells. *Oncotarget* 2015; **6**(31): 32138-32153.
714 doi:10.18632/oncotarget.5171
- 715 52. Maucourant C, Filipovic I, Ponzetta A, et al. Natural killer cell immunotypes
716 related to COVID-19 disease severity. *Sci Immunol* 2020; **5**(50): eabd6832.
717 doi:10.1126/sciimmunol.abd6832
- 718 53. Kumar B V, Ma W, Miron M, et al. Human Tissue-Resident Memory T Cells Are
719 Defined by Core Transcriptional and Functional Signatures in Lymphoid and
720 Mucosal Sites. *Cell Reports* 2017; **20**(12): 2921-2934.
721 doi:10.1016/j.celrep.2017.08.078
- 722 54. Fonseca R, Beura LK, Quarnstrom CF, et al. Developmental plasticity allows
723 outside-in immune responses by resident memory T cells. *Nat Immunol* 2020;
724 **21**(4): 412-421. doi:10.1038/s41590-020-0607-7
- 725 55. Weizman O El, Adams NM, Schuster IS, et al. ILC1 Confer Early Host Protection
726 at Initial Sites of Viral Infection. *Cell* 2017; **171**(4): 795-808.e12.
727 doi:10.1016/j.cell.2017.09.052
- 728 56. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of
729 SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong
730 Cohort: Systematic Review and Meta-analysis. *Gastroenterology* 2020; **159**(1):
731 81-95. doi:10.1053/j.gastro.2020.03.065
- 732 57. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects
733 human gut enterocytes. *Science* 2020; **369**(6499): 50-54.
734 doi:10.1126/science.abc1669
- 735 58. Schaefer IM, Padera RF, Solomon IH, et al. In situ detection of SARS-CoV-2 in
736 lungs and airways of patients with COVID-19. *Mod Pathol* 2020. Epub ahead of

- 737 print. doi:10.1038/s41379-020-0595-z
- 738 59. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal
739 Infection of SARS-CoV-2. *Gastroenterology* 2020; **158**(6): 1831-1833.e3.
740 doi:10.1053/j.gastro.2020.02.055
- 741 60. Winkler C, Hochdörfer T, Israelsson E, et al. Activation of group 2 innate
742 lymphoid cells after allergen challenge in asthmatic patients. *J Allergy Clin*
743 *Immunol* 2019; **144**(1): 61-69.e7. doi:10.1016/j.jaci.2019.01.027
- 744

745 **FIGURE LEGENDS**

746

747 **Figure 1. Experimental design and COVID-19 cohort characteristics. (A)**

748 Schematic representation of the cohort characteristics (left), materials and methods

749 (middle) and the type of analysis performed using the flow cytometric data (right). **(B)**

750 Graphical overview of all COVID-19 patients (n=23) illustrating clinical events from the

751 day of the patient symptom debut. Depicted are the day of the SARS-CoV-2 PCR test,

752 hospitalization and blood sampling. For all the severe patients and three of the

753 moderate patients the day of the intensive care unit (ICU) admission and discharge is

754 indicated. Furthermore, the day of intubation/extubation of the severe patients is

755 shown. Lastly, depicted is the day of hospital discharge for 22 out of 23 patients and

756 the number of deceased patients (n=4). One patient from the severe group (#11) is

757 still in ECMO with ongoing hospitalization (>64 days).

758

759 **Figure 2. Depletion and altered frequency of ILCs in the peripheral blood of**

760 **COVID-19 patients. (A)** Representative flow cytometry plots depicting the gate for the

761 identification of the total ILCs in one control donor, one moderate and one severe

762 COVID-19 patient. **(B)** Bar plot summaries of (A) the percentage (left) and absolute

763 counts (per mL blood) (right) of total ILCs in control donors (n=16), moderate (n=11)

764 and severe (n=12) COVID-19 patients. **(C)** Representative flow cytometry plots

765 depicting total ILCs gated as: ILCp, ILC2 (CD117^{+/+}) (upper row) and ILC1 (lower row)

766 in one control donor, one moderate and one severe COVID-19 patient. **(D)** Bar plot

767 summaries of (C) absolute counts of ILC1, ILC2 and ILCp subsets (per mL blood) in

768 control donors (n=16), moderate (n=11) and severe (n=11) COVID-19 patients. **(E)**

769 Bar plot summaries of (C) the percentage of the ILC1, ILC2 and ILCp of total ILCs in

770 control donors (n=16), moderate (n=11) and severe (n=11) COVID-19 patients. **(F)**

771 Bar plot summaries of (C) the percentage of CD117⁺ and CD117⁻ ILC2 of total ILCs in

772 control donors (n=16), moderate (n=11) and severe (n=9) COVID-19 patients. **(B, C,**

773 **E, F)** statistical differences were tested using Kruskal-Wallis test followed by Dunn's

774 multiple comparisons. Numbers in flow cytometry plots indicate percentage of cells

775 within the mother gate. Bar graphs are shown as median ± IQR, *p < 0.05, ** p < 0.01,

776 *** p < 0.001. Patients with low cell numbers (less than 20 events) in the corresponding

777 gate were removed from the analysis.

778

779 **Figure 3. ILCs reveal an activated and migratory profile in peripheral blood of**
780 **COVID-19 patients. (A)** Bar plot summaries showing the percentages of the indicated
781 markers in total ILCs in control donors (n=16), moderate (n=11) and severe (n=11)
782 COVID-19 patients. **(B)** PCA plot of total ILCs from control donors (n=16), moderate
783 (n=11) and severe (n=11) COVID-19 patients based on the cell surface markers
784 presented in (A). **(C)** Bar plot summaries showing the percentages of the indicated
785 markers in ILC1 subset in control donors (n=16), moderate (n=10) and severe (n=11)
786 groups. **(D)** PCA plot of ILC1 showing the contribution of cell surface markers indicated
787 in (C). **(E)** Bar plot summaries showing the percentages of the indicated markers in
788 ILC2 subset in control donors (n=16), moderate (n=11) and severe (n=9) groups. **(F)**
789 PCA plot of ILC2 showing the contribution of cell surface markers indicated in (E). **(G)**
790 Bar plot summaries showing the percentages of the indicated markers in ILCp subset
791 in control donors (n=16), moderate (n=10) and severe (n=10) groups. **(H)** PCA plot of
792 ILCp showing the contribution of cell surface markers indicated in (G). **(A, C, E, G)**,
793 statistical differences were tested using Kruskal-Wallis test followed by Dunn's multiple
794 comparisons. Bar graphs are shown as median \pm IQR, *p < 0.05, ** p < 0.01, *** p <
795 0.001. Patients with low cell numbers (less than 20 events) in the corresponding gate
796 were removed from the analysis. In PCA plots each dot represents one donor.
797 Deceased patients in the severe group are indicated by a black dot.

798

799 **Figure 4. Dimensionality reduction analysis of ILCs in the peripheral blood of**
800 **COVID-19 patients distinguishes moderate and severe patients. (A)** Top row:
801 UMAP of total ILCs from controls and COVID-19 patients (All donors) and overlaid by
802 patient groups: of control donors (yellow), moderate COVID-19 patients (blue) and
803 severe COVID-19 patients (red) (from left to right). Middle and bottom rows: UMAP
804 (All donors) colored according to the fluorescence intensity expression (median) of the
805 indicated phenotypic markers. **(B)** UMAP of the total ILCs overlaid with the 14 clusters
806 identified by Phenograph. **(C)** Heatmap displaying the median of expression of the
807 indicated markers for each Phenograph clusters. Each cluster was assigned an ILC
808 subset identity (ILC1, ILC2, ILCp and CD117⁻ ILC) based on the heatmap and the
809 relative expression levels in (D). **(D)** Relative expression level of markers in the
810 Phenograph clusters grouped by ILC subsets (ILC1, ILC2 and ILCp). Grey lines in
811 each graph are the rest of clusters not belonging to the ILC subset depicted. **(E)** Far
812 left column: manually defined gates of total ILCs and ILC subsets ILC1, ILC2 and ILCp

813 overlaid on the All donors UMAP in (A). Right columns: UMAP of total ILCs overlaid
814 with the 14 ILCs clusters identified by Phenograph and displayed according to patient
815 group (columns) and ILCs subsets (rows). Colors used for the clusters correspond to
816 the colors used in Fig. 4B-D. **(F)** Stacked bar graph of the percentage of all
817 Phenograph-identified clusters out of total ILCs in controls (grey), moderate (blue) and
818 severe COVID-19 patients (red). **(G)** Left: stacked bar graph of the percentage of the
819 Phenograph-identified clusters belonging to ILC1 out of total ILCs in controls (grey),
820 moderate (blue) and severe (red) COVID-19 patients. Right: Percentage of the sum of
821 events corresponding to the ILC1 Phenograph-identified clusters (14,2,6) out of total
822 ILCs, in controls (n=5), moderate (n=5), and severe COVID-19 patients (n=9). **(H)** Left:
823 stacked bar graph of the percentage of the Phenograph-identified clusters belonging
824 to ILC2 out of total ILCs in controls, moderate, and severe COVID-19 patients. Right:
825 Percentage of the sum of events corresponding to the ILC2 Phenograph-identified
826 clusters (8,10,12) out of total ILCs, in controls (n=9), moderate (n=9), and severe
827 COVID-19 patients (n=9). **(I)** Left: stacked bar graph of the percentage of the
828 Phenograph-identified clusters belonging to ILCp out of total ILCs in controls,
829 moderate, and severe COVID-19 patients. Right: percentage of the sum of events
830 corresponding to the ILCp Phenograph-identified clusters (3,4,1,7,11,9,5) out of total
831 ILCs, in controls (n=9), moderate (n=9), and severe COVID-19 patients (n=9). **(G-I)**
832 Patients with less than 10 events per ILC subsets (defined by Phenograph-identified
833 clusters) were excluded from analysis. Statistical differences were tested using the
834 Kruskal-Wallis test followed by Dunn's multiple comparisons test. Bar graphs are
835 shown as median \pm IQR, *p < 0.05, ** p < 0.01.

836

837 **Figure 5. Activation status and homing profile of peripheral blood ILCs**
838 **associate with inflammation markers in COVID-19 patients.** Spearman
839 correlations between **(A)** serum IL-6 levels (pg/ml) and the percentage of CD69⁺ ILC
840 and CD69⁺ ILCp; **(B)** serum IL-10 relative levels and the percentage of CD69⁺ ILC in
841 COVID-19 patients; **(C)** serum CXCL10 levels (pg/ml) and the percentage of CD69⁺
842 ILC and CD69⁺ ILCp; **(D)** serum CXCL10 and CXCL11 levels (pg/ml) and the
843 percentage of CXCR3⁺ ILCs; **(E)** serum CCL20 levels (pg/ml) and the percentage of
844 ILC2 and CCR4⁺ ILCs. IL-6, CXCL10, CXCL11 and CCL20 serum absolute levels
845 were measured with Magnetic Luminex Screening assay, and IL-10 relative levels with
846 a proximity extension assay, where data is shown as normalized protein expression


847 (NPX). Blue circles: moderate COVID-19 patients (n=11); red circles: severe COVID-
848 19 patients (n=11); black circles: deceased severe COVID-19 patients (n=4). $p < 0.05$
849 was considered statistically significant. r_s : Spearman's rank correlation coefficient.

850

851 **Figure 6. Peripheral blood ILC subsets associate with biochemical and**
852 **hematological parameters that reflect COVID-19 severity. (A)** Principal
853 Component Analysis (PCA) of COVID-19 patients displaying the distribution and
854 segregation of COVID-19 patients according to clinical and laboratory parameters. **(B)**
855 Bar plot showing the percentage contribution of each clinical or laboratory parameter
856 to principal component 1 (PC1). **(C)** Correlation plots between percentage of ILC1 and
857 the indicated hematological (Hi PLT), organ damage (LDH) and other parameters
858 (SARS-CoV-2 IgG and DPS) in COVID-19 patients (moderate n=11; severe n=11). **(D)**
859 Correlation plots between percentage of ILC2 and the indicated hematological (Hi Leu,
860 Hi N Φ , Hi PLT and DPS), coagulation (D-dimer), organ damage (myoglobin, troponin
861 and LDH) and other (SARS-CoV-2 IgG and DPS) parameters in COVID-19 patients
862 (moderate n=11;severe n=11). Hi N Φ : highest neutrophil count +/-24h from sampling;
863 PF ratio: PaO₂/FiO₂ ratio (mm Hg) at sampling; Hi PLT: highest platelet count before
864 sampling (b.s); IL-6: IL-6 levels at the time of sampling; NT: neutralizing antibody titers
865 at sampling; CRP: highest C-reactive protein +/-24h; LDH: highest lactate
866 dehydrogenase b.s; PCT: highest procalcitonin +/-24h; Days O₂: days of oxygen
867 treatment; Low Lympho: Lowest lymphocyte count +/-24h; Low P-Alb: lowest P-
868 Albumin +/-24h; Hi Leu: highest leukocyte count +/-24h; Low Leu: Lowest leukocyte
869 count +/-24h; D-dimer: highest D-dimer level +/-24h; Ferritin: highest ferritin level +/-
870 24h; SARS-CoV-2 IgG: SARS-CoV-2 IgG antibodies (AU/mL); DPS: days post
871 symptom debut to sampling; Days Hosp: days of hospitalization until sampling.
872 Spearman's rank correlation test was applied for assessing correlations between
873 variables.

874

Figure 1.



B




Figure 2.




Figure 3.




Figure 4.

All rights reserved. No reuse allowed without permission.




Figure 5.






Figure 6:


A




B



C



D



TABLES

Table 1. Donor characteristics

	Controls (n=16)	Moderate (n=11)	Severe (n=12)
Risk factors			
Age, median (range)	54 (34-69)	56 (18-67)	59.5 (40-74)
Gender, male, n (%)	10 (62.5)	7 (63.6)	10 (83.3)
BMI†, median (range)	n/a	27 (23-35.06)	29.5 (23-55)
Smoker (Yes/No/Prior/Unclear, %)	n/a	10/36/27/27	8.3/58.3/25/8.3
Pre-existing pathologies			
Asthma, n (%)	n/a	1 (9)	2 (16.6)
Diabetes Type 2, n (%)	n/a	1 (9)	1 (8.3)
Hypertension, n (%)	n/a	2 (18)	4 (33.3)
Coronary heart disease, n (%)	n/a	1 (9)	0 (0)
Viremia at time of sampling, n (%)	n/a	2 (18)	7 (58.3)
Symptoms on admission			
Fever, n (%)	n/a	11 (100)	12 (100)
Cough, n (%)	n/a	10 (91)	11 (91.6)
Dyspnea, n (%)	n/a	11 (100)	12 (100)
Body ache, n (%)	n/a	6 (54.5)	6 (50)
Gastrointestinal, n (%)	n/a	2 (18)	2 (16.6)
Days from symptom debut to admission, median (range)	n/a	7 (4-14)	9 (3-14)
Days from symptom debut to sampling, median (range)	n/a	14 (6-19)	14 (5-24)
Peak oxygen need			
None, n (%)	n/a	2 (18)	0 (0)
Low flow <10L/min, n (%)	n/a	5 (45.4)	0 (0)
Low flow 10-15L/min, n (%)	n/a	4 (36.4)	0 (0)
Ventilator, n (%)	n/a	0 (0)	12 (100) ‡
PaO2/FiO2 ratio, median mmHg (range)	n/a	323 (112-523)	136 (52-192)
Duration of oxygen treatment in days, median (range)	n/a	7 (0-13)	22 (7-33), 1 still ongoing
Treatments prior to sampling			
Anti-coagulant, (Low-molecular- weight-heparin), n (%)	n/a	11 (100)	11 (91.6), 1 unclear
Corticosteroids, n (%)	n/a	4 (36.4)	8 (66.6)
Antibiotics, n (%)	n/a	5 (45.4), all Cefotaxim	7 (58.3) Cefotaxim, 1 (8.3) all the above
Antiviral/Cytokine inhibitors, n (%)	n/a	0 (0)	2 (16.6): Remdesivir, Tocilizumab
Laboratory testing			
PCR positivity in nasopharynx/sputum, n (%)	n/a	11 (100), n=1 sputum	12 (100), all nasopharynx
PCR positivity in serum, n (%)	n/a	2 (18)	7 (58.3)
Antibody reactivity, n (%)	0 (0)	7 (63.3) reactive, 1 (9) gray zone	11 (91.6) reactive, 1 (8.3) gray zone
Neutralizing antibody titers, median (range)	0 (0)	960 (0-2560)	1440 (60-5120)

Clinical course

Days in ICU from admission until discharge, median (range)	n/a	For 3/11 patients: 7 (5-8)	For 11/12: 18 (7-27), 1 ongoing
Days of intubation, median (range)	n/a	0 (0), n=3 n/a	18 (1-28), 1 ongoing
Days hospitalized, median (range)	n/a	11 (6-14)	22 (16-58), 1 ongoing
Radiological bilateral infiltrations, n (%)	n/a	6 (54.5), n=5 n/a	12 (100)
Positive culture findings in blood +/- 5 days from sampling, n (%)	n/a	0 (0)	4 (33.3)
Positive culture findings in lower respiratory tract +/- 5 days from sampling, n (%)	n/a	0 (0)	7 (58.3)
Pulmonary embolism, n (%)	n/a	0 (0)	2 (16.6)

Outcome

Discharged, n (%)	n/a	11 (100)	8 (66.6)
Deceased, n (%)	n/a	0 (0)	4 (33.3)

†BMI: Body Mass Index (18.5-24.9 normal; 25-29.9 overweight; >30 obesity), ‡ n=1 patient in ECMO, n/a: not available

Table 2. Laboratory parameters of COVID-19 patients

	Reference	Moderate (n=11) Median peak (range)	Severe (n=12) Median peak (range)	P-value
Before study sampling				
C-reactive protein, mg/L	<3	176 (34 - 346)	310 (124 - 452)	0.0268
Procalcitonin, µg/L	<0.5	0.4 (0.11 - 66)	1.2 (0.19 - 10)	0.1335
D-dimer, mg/L	<0.56	0.88 (0.33 - 1.5)	2.5 (0.9 - 5.4)	<0.0001
Ferritin, µg/L	10-150	866 (222 - 2293)	1946 (305 - 5500)	0.0156
Fibrinogen, g/L	2-4.2	6.1 (4.9 - 10.2), n=8 n/a	7.2 (4.1 - 9.6)	0.8066
Lactate dehydrogenase, µkat/L	<3.5	5.7 (0.89 - 13.7)	10.9 (7 - 23)	0.0002
Alanine aminotransferase, µkat/L	<0.76	0.8 (0.51 - 3.43)	1.31 (0.67 - 2.52)	0.3788
Bilirubin, µmol/L	<26	8 (4 - 15)	12 (7 - 81)	0.0063
Creatinine, µmol/L	<90	77 (46 - 96)	87 (54 - 326)	0.0938
Prothrombin complex, INR	<1.2	1 (0.9 - 1.1)	1.1 (1 - 1.4)	0.0077
Troponin T, ng/L	<15	9.5 (5 - 19), n=1 n/a	19 (5 - 601)	0.0159
Myoglobin, µg/L	<73	36.5 (22 - 158), n=5 n/a	658 (46 - 6400)	0.0008
Lymphocytes, lowest, x10 ⁹ /L	1.1 - 3.5	0.7 (0.3 - 1.9)	0.5 (0.2 - 1.1)	0.1443
Neutrophils, lowest, x10 ⁹ /L	1.6 - 5.9	3.7 (0.5 - 6.5)	6.3 (3.3 - 15.9)	0.0195
Platelets, lowest, x10 ⁹ /L	165 - 387	228 (131 - 342)	212 (115 - 315)	0.7980
Platelets, highest, x10 ⁹ /L	165 - 387	401 (152 - 659)	427.5 (214 - 770)	0.7399
At study sampling (+/- 24h)				
C-reactive protein, mg/L	<3	103 (20 - 394), n=1 n/a	258 (51 - 346)	0.0249
Procalcitonin, µg/L	<0.5	0.36 (0.12 - 866), n=2 n/a	0.945 (0.16 - 10)	0.3358
D-dimer, mg/L	<0.56	0.60 (0.36 - 1.56), n=1 n/a	3.7 (0.74 - 7.6)	0.0002
Ferritin, µg/L	10 - 150	847 (161 - 2370)	1852 (312 - 4306), n=1 n/a	0.0336
Fibrinogen, g/L	2 - 4.2	4.9 (4.7 - 10.2), n=8 n/a	7.4 (4.1 - 9.6), n=1 n/a	0.6786
Bilirubin, µmol/L	<26	6 (0 - 11)	9 (6 - 81)	0.0011
Creatinine, µmol/L	<90	69 (36 - 78)	73.5 (44 - 326)	0.2536
Hemoglobin, g/L	117 - 153	118 (90 - 145)	112.5 (84 - 146)	0.5553
P-Albumin, g/L	36 - 48	27 (21 - 37), n=4 n/a	18 (16 - 22)	0.0188
Prothrombin complex, INR	<1.2	1.05 (0.9 - 1.1), n=5 n/a	1.1 (0.9 - 1.4)	0.0980
Troponin T, ng/L	<15	7.5 (5 - 10), n=3 n/a	17.5 (5 - 434)	0.0325
Lymphocytes, lowest, x10 ⁹ /L	1.1 - 3.5	1.3 (0.3 - 2.4)	0.65 (0.3 - 1.8)	0.0231
Neutrophils, highest, x10 ⁹ /L	1.6 - 5.9	4.6 (0.9 - 9.3)	11.2 (8.5 - 16.7)	<0.0001
Platelets, lowest, x10 ⁹ /L	165 - 387	345.5 (131 - 642), n=1 n/a	363 (179 - 502)	0.9876
Leukocytes, highest, x10 ⁹ /L	3.5 - 8.8	7.1 (1.5 - 12.6)	12.6 (9.2 - 18.4)	0.0001
Leukocytes, lowest, x10 ⁹ /L	3.5 - 8.8	6.7 (1 - 10.5)	9.8 (7.6 - 15.7)	0.0003
At study sampling (+/- 5d)				
Interleukin-6, ng/L	<7	62 (2 - 150), n=2 n/a	472.5 (33 - 8093)	0.0035

P-value: Mann-Whitney test, n/a: not available